Lipoprotein(a) and progression of aortic valve calcification: a case of collider bias? Reply
- PMID: 36610071
- PMCID: PMC9925270
- DOI: 10.1093/eurheartj/ehac742
Lipoprotein(a) and progression of aortic valve calcification: a case of collider bias? Reply
Conflict of interest statement
Conflict of interest: E.S.G.S. has received research grants/support to his institution from Amgen, Sanofi, Resverlogix, and Athera and has served as a consultant for Amgen, Sanofi, Esperion, Novartis, and Ionis Pharmaceuticals. All other authors report no conflict of interest.
Comment on
-
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification.Eur Heart J. 2022 Oct 14;43(39):3960-3967. doi: 10.1093/eurheartj/ehac377. Eur Heart J. 2022. PMID: 35869873 Free PMC article.
-
Lipoprotein(a) and progression of aortic valve calcification: a case of collider bias?Eur Heart J. 2023 Feb 14;44(7):624-625. doi: 10.1093/eurheartj/ehac638. Eur Heart J. 2023. PMID: 36610068 Free PMC article. No abstract available.
